Key facts
- This page summarizes Andrew A. Hindman's Form 4 filing for Theravance Biopharma, Inc. (TBPH).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 22 Nov 2022, 15:07.
Andrew A. Hindman - 18 Nov 2022 Form 4 Insider Report for Theravance Biopharma, Inc. (TBPH)
- Reporting relationship
- SVP, CHIEF FINANCIAL OFFICER
- Issuer ticker
- TBPH
- Reported as of
- 18 Nov 2022
- Net transaction value
- -$988,110
- SEC form
- 4
- Accepted by SEC
- 22 Nov 2022, 15:07:30 UTC
- Prior SEC filing
- 23 Aug 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Brett A. Grimaud, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Andrew A. Hindman filed Form 4 for Theravance Biopharma, Inc. (TBPH) on 22 Nov 2022.
Change
- Previous filing in this sequence was filed on 23 Aug 2022.
- Current net transaction value: -$988,110.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TBPH
transaction
Ordinary Shares
Sale
- Transaction value
- $716,242
- Shares
- -65,000
- Change %
- -14%
- Price
- $11.02
- Shares after
- 409,771
- Date
- 18 Nov 2022
- Ownership
- Direct
- Footnotes
- F1, F2
TBPH
transaction
Ordinary Shares
Tax liability
- Transaction value
- $271,868
- Shares
- -25,057
- Change %
- -6.1%
- Price
- $10.85
- Shares after
- 384,714
- Date
- 20 Nov 2022
- Ownership
- Direct
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
This transaction was executed in multiple trades at prices from $10.7891 to $11.2750. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.
Footnote F2
Includes 1,264 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on November 15, 2022.
Footnote F3
Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.